Eli Lilly just can’t get enough weight loss therapies or acquisitions to bolster its pipeline. The Indianapolis-based company has signed off on a $1.92 billion deal, which covers an upfront payment and potential milestones, for Boston-based Versanis and lead asset bimagrumab.

礼来公司无法获得足够的减肥疗法或收购来支持其管道。这家位于印第安纳波利斯的公司已经签署了19.2亿美元的协议，涵盖了波士顿Versanis和领先资产bimagrumab的预付款和潜在里程碑。

The monoclonal antibody is already in a phase 2 trial both alone and in combination with semaglutide in adults who are overweight or obese.

单克隆抗体已经在超重或肥胖的成年人中单独或与semaglutide联合进行2期试验。

Novo Nordisk’s GLP-1 receptor agonist semaglutide—which is marketed as Wegovy to treat obesity—is know as an incretin-based therapy. Combining incretins with bimagrumab “has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications,” Lilly explained in this morning’s release..

诺和诺德的GLP-1受体激动剂semaglutide以Wegovy销售以治疗肥胖症被称为基于肠降血糖素的疗法。将肠促胰岛素与bimagrumab联合使用“有可能在保持肌肉质量的同时进一步减少脂肪量，并可能为肥胖和肥胖相关并发症患者带来更好的结果”，礼来解释今天早上的发布。。

“Lilly is committed to investigating potential new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans,” Ruth Gimeno, Ph.D., Lilly’s group vice president for diabetes, obesity and cardiometabolic research, said in the release. “By unifying the knowledge and expertise in incretin biology at Lilly with the deep understanding of activin biology at Versanis, we aim to harness the potential benefits of such combinations for patients.”.

礼来公司糖尿病，肥胖和心脏代谢研究小组副总裁Ruth Gimeno博士说：“礼来公司致力于研究潜在的新药来对抗心脏代谢疾病，包括肥胖，这是一种影响1亿多美国人的慢性疾病。”发布。“通过将礼来公司肠降血糖素生物学的知识和专业知识与Versanis对激活素生物学的深刻理解相结合，我们的目标是利用这种组合对患者的潜在益处。”。

Last month, Lilly posted phase 2 data from one of its own incretin drugs, called retatrutide, which showed an average reduction in body weight of 24%. The results blow out of the water data from the currently approved medicines—Wegovy and another incretin drug by Lilly called Mounjaro. Lilly’s offering is approved for Type 2 diabetes but has been used off label for obesity..

上个月，礼来公司发布了自己的一种名为retatrutide的肠降血糖素药物的第二阶段数据，显示体重平均下降24%。结果从目前批准的药物Wegovy和Lilly的另一种肠降血糖素药物Mounjaro的水数据中吹出。礼来公司的产品已被批准用于2型糖尿病，但已被用于肥胖标签外。。

Privately owned Versanis was founded in 2021 by biotech investment firm Aditum Bio, which set up the company specifically to develop bimagrumab for the treatment of metabolic diseases and obesity after the firm licensed the drug from Novartis.

私人拥有的Versanis成立于2021年，由生物技术投资公司Aditum Bio创立，该公司专门开发bimagrumab，用于治疗代谢性疾病和肥胖症，该公司从诺华公司许可该药物。

Bimagrumab is a monoclonal antibody to activin type II receptors, which is designed to block the binding of ligands including myostatin, activins and GDF11. The drug has had a checkered past, having failed a phase 2b/3 study for a rare muscle-wasting disease called sporadic inclusion body myositis way back in 2016..

Bimagrumab是激活素II型受体的单克隆抗体，其被设计用于阻断包括肌肉生长抑制素，激活素和GDF11的配体的结合。这种药物在过去已经经历了一个检查，在2016年之前，一项罕见的肌肉萎缩性疾病（称为散发性包涵体肌炎）的2b/3期研究失败了。。

Aditum wasn’t the only one to see bimagrumab’s potential in obesity, with European life sciences investors Medicxi co-leading a $70 million series A financing round for Versanis in August 2021.

Aditum并不是唯一一个看到bimagrumab在肥胖方面具有潜力的人，欧洲生命科学投资者Medicxi于2021年8月共同领导了7000万美元的Versanis系列a融资轮。

For Lilly’s part, today’s acquisition continues a busy summer of M&A. The Big Pharma spent June handing over upfront payments of $34.6 million and a whopping $2.4 billion to acquire Type 1 diabetes partner Sigilon Therapeutics and IL-17-focused Dice Therapeutics, respectively. With Lilly keeping the upfront fee for Versanis under wraps for now, it’s hard to decipher how today’s deal compares to its recent spending spree..

就礼来而言，今天的收购继续是M＆a繁忙的夏天。大型制药公司6月花了3460万美元和24亿美元的预付款，分别收购了1型糖尿病合作伙伴Sigilon Therapeutics和IL-17聚焦骰子疗法。随着礼来公司目前对Versanis的前期费用的限制，很难解读今天的交易与最近的支出支出相比如何。。